Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer
Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc
metallopeptidase with the highest expression levels found in the nervous and prostatic …
metallopeptidase with the highest expression levels found in the nervous and prostatic …
[HTML][HTML] Advances in PSMA theranostics
TM Jeitner, JW Babich, JM Kelly - Translational Oncology, 2022 - Elsevier
The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …
metastatic castration-resistant prostate cancer has stimulated the development of multiple …
Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage
L Schwab, L Goroncy, S Palaniyandi, S Gautam… - Nature medicine, 2014 - nature.com
Acute graft-versus-host disease (GVHD) considerably limits wider usage of allogeneic
hematopoietic cell transplantation (allo-HCT). Antigen-presenting cells and T cells are …
hematopoietic cell transplantation (allo-HCT). Antigen-presenting cells and T cells are …
High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer
S Minner, C Wittmer, M Graefen, G Salomon… - The …, 2011 - Wiley Online Library
BACKGROUND Prostate specific membrane antigen (PSMA) is a suggested target for
antibody‐based therapy of prostate cancer potentially involved in the regulation of cell …
antibody‐based therapy of prostate cancer potentially involved in the regulation of cell …
Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging
Purpose 68 Ga-PSMA-11 is a novel PET tracer suggested to be used for imaging of
advanced prostate cancer. In this study, we aimed to present a detailed biodistribution of 68 …
advanced prostate cancer. In this study, we aimed to present a detailed biodistribution of 68 …
Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives
P Backhaus, B Noto, N Avramovic, LS Grubert… - European journal of …, 2018 - Springer
Background Prostate-specific membrane antigen (PSMA) is the up-and-coming target for
molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA …
molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA …
[HTML][HTML] Prostate specific membrane antigen—a target for imaging and therapy with radionuclides
K Bouchelouche, PL Choyke, J Capala - Discovery medicine, 2010 - ncbi.nlm.nih.gov
Prostate cancer continues to represent a major health problem, and yet there is no effective
treatment available for advanced metastatic disease. Thus, there is an urgent need for the …
treatment available for advanced metastatic disease. Thus, there is an urgent need for the …
The potential of CAR T cell therapy for prostate cancer
Chimeric antigen receptor (CAR) T cell immunotherapy involves the genetic modification of
the patient's own T cells so that they specifically recognize and destroy tumour cells …
the patient's own T cells so that they specifically recognize and destroy tumour cells …
Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT
TJWK Nulent, MH Valstar, B de Keizer… - Oral surgery, oral …, 2018 - Elsevier
Objectives Prostate-specific membrane antigen (PSMA) positron emission
tomography/computed tomography (PET/CT) is used for detection and (re) staging of …
tomography/computed tomography (PET/CT) is used for detection and (re) staging of …
Prostate-specific membrane antigen-based imaging
JR Osborne, NH Akhtar, S Vallabhajosula… - … Oncology: Seminars and …, 2013 - Elsevier
Prostate cancer (CaP) is the most common noncutaneous malignancy affecting men in North
America. Despite significant efforts, conventional imaging of CaP does not contribute to …
America. Despite significant efforts, conventional imaging of CaP does not contribute to …